*Disclaimer

MAYNE PHARMA GROUP LIMITED (ASX: MYX)

🔗 📄 📈

MYX: MYX provides investor update & announces on market buyback

MAYNE PHARMA GROUP LIMITED

2023-05-10 08:19:00

MYX: MYX completes sale of US retail generics business for US$90m

MAYNE PHARMA GROUP LIMITED

2023-04-11 08:14:00

MYX: Update on sale of US retail generics portfolio

MAYNE PHARMA GROUP LIMITED

2023-04-03 08:32:00

MYX: Mayne Pharma announces cancellation of capital return

MAYNE PHARMA GROUP LIMITED

2023-02-28 09:03:00

MYX: Mayne Pharma announces sale of US retail generics business

MAYNE PHARMA GROUP LIMITED

2023-02-27 13:24:00

MYX: Mayne Pharma provides update on capital management timeline

MAYNE PHARMA GROUP LIMITED

  1. Mayne Pharma Group Limited announced a revision to the timetable associated with the capital management initiatives.
  2. The capital management initiatives are up to A$113 million following the completion of the sale of Metrics Contract Services.
  3. The package proposed comprises a fully franked special dividend of approximately $47.3 million and a pro-rata capital return of up to $65.5 million.

2023-01-12 08:20:00

MYX: MYX completes TherapeuticsMD product licensing transaction

MAYNE PHARMA GROUP LIMITED

  1. Mayne Pharma Group Limited (ASX: MYX) has completed an exclusive product licensing transaction with TherapeuticsMD, Inc (TXMD).
  2. The agreement includes a portfolio of on-market women’s health products, three patent protected novel women’s health products, and a portfolio of prenatal vitamins in the US.
  3. Mayne Pharma paid TXMD a cash consideration of US$140m and a US$13.1m payment for acquired net working capital and pre-paid royalties.

2023-01-03 08:28:00